Withdrawal syndromes and the cessation of antihypertensive therapy.

Article Details

Citation

Copy to clipboard

Hart GR, Anderson RJ

Withdrawal syndromes and the cessation of antihypertensive therapy.

Arch Intern Med. 1981 Aug;141(9):1125-7.

PubMed ID

6114720 [ View in PubMed

]

Abstract

A review of the available literature concerning sudden withdrawal of antihypertensive drugs shows that withdrawal syndromes after cessation of such agents have occurred with beta-blockers, methyldopa, clonidine hydrochloride, guanabenz, and bethanidine sulfate. Most commonly, these syndromes are limited to nervousness, tachycardia, headache, and nausea 36 to 72 hours after cessation of the drug. In rare cases, serious exacerbation of myocardial ischemia (beta-blockers) or hypertension (clonidine, methyldopa) may occur in the posttreatment period. The withdrawal syndromes generally respond promptly to reinstitution of antihypertensive therapy. The infrequent occurrence of withdrawal syndromes should not discourage use of these efficacious agents.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Bethanidine	Beta adrenergic receptor (Protein Group)	Protein group	Humans	Unknown	Antagonist	Details